| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4025939 | Ophthalmology | 2014 | 11 Pages |
Abstract
Long-term outcomes in BRVO patients treated with ranibizumab were excellent, and although half still required occasional injections after 4 years, they maintained good visual potential. A substantial minority (44%) of patients with ranibizumab-treated CRVO had edema resolution and a good outcome within 4 years, but most (56%) still required frequent injections, had reduced visual potential, and have a guarded prognosis.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Peter A. MD, Raafay MD, Joel MD, PhD, David M. MD, David S. MD, Jeffrey S. MD, Dennis M. MD, Leonard MD, PhD, Arun MD, RETAIN Study Group RETAIN Study Group,